Private company
Who owns SCRI Oncology, LLC
One company in the researched set discloses a stake in SCRI Oncology, LLC, none of it sized by anyone who discloses it. SCRI Oncology, LLC is private, so no 13F reports it: a 13F covers exchange listed positions only. These figures exist because each holder disclosed the stake in its own filings.
SCRI Oncology, LLC - Profile
- Type
- joint venture
- Based in
- United States
- Founded
- 2022
SCRI Oncology, LLC trades as Sarah Cannon Research Institute and is one of the largest cancer research networks in the United States, run from Nashville, Tennessee. It was formed on 31 October 2022 by combining McKesson's US Oncology Research, which contributed roughly 60 research sites and about 500 active trials embedded in community oncology practices, with HCA Healthcare's Sarah Cannon Research Institute, which contributed early phase drug development expertise, clinical trial site management and a contract research organisation. The business designs and runs oncology trials for pharmaceutical sponsors, manages the sites where those trials are conducted, and matches patients treated in community practices to studies they would otherwise have to travel to reach. Its network covers about 1,500 physicians at more than 200 locations across over 20 states, and it has run more than 900 first in human cancer trials.
Source
SCRI Oncology, LLC files nothing with the SEC, so none of this comes from a filer record. The description was written for this site in August 2026 from McKesson Corporation Form 10-K for the year ended 31 March 2024 (SEC), McKesson and HCA Healthcare Announce Plans to Form an Oncology Research Joint Venture (HCA Healthcare investor release, 2022) and Sarah Cannon Research Institute, About Us. The ownership figures below come from the holders' filings instead, and are sourced row by row.
The disclosed stakes
One row per position. Where a holder reports the same company in two share classes, both rows are shown rather than summed, because the class is part of a position's identity.
Where each figure comes from
A private stake has no ownership form behind it, so the source is always the holder's own filing or disclosure. Anything modelled says so, with the arithmetic.
- McKesson Corporation. Same combined-balance limitation as ClarusONE and Vantage: no individual value or percentage split out of the $395 million (31 Mar 2026) / $380 million (31 Mar 2025) combined noncontrolling-interest figure. Recorded unsized because the investee and McKesson's controlling, consolidating position are named in the filing. Acquisition date not disclosed in the fetched filings. source
What this page is not
It is not a complete register. It lists the holders who happen to be inside the researched set and disclosed the stake themselves. A private company can have many other shareholders, and nothing here rules them out: venture investors, founders and employees usually appear in no public filing at all. Percentages are of SCRI Oncology, LLC where a holder stated one, and are missing where no holder did.